Intravenous immunoglobulin (IVIG)

DRUG15 trials

Sponsors

National Institute of Neurological Disorders and Stroke (NINDS), Masonic Cancer Center, University of Minnesota, University of California, San Diego, University of Massachusetts, Worcester, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Conditions

Acute Exacerbation of Idiopathic Pulmonary FibrosisAgammaglobulinemiaAutoimmune EncephalitisAutoimmune Encephalitis Caused by N-Methyl D-Aspartate Receptor AntibodyAutoimmune Encephalitis Caused by N-Methyl D-Aspartate Receptor Antibody (Disorder)Biliary AtresiaChediak-Higashi SyndromeChronic Obstructive Pulmonary Disease

Phase 1

Infliximab (Remicade) for Patients With Acute Kawasaki Disease

CompletedNCT00271570

University of California, San DiegoKawasaki Disease

Start: 2004-04-30End: 2006-10-31Updated: 2010-06-14

Safety Study of Intravenous Immunoglobulin (IVIG) Post-Portoenterostomy in Infants With Biliary Atresia

CompletedNCT01854827

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Biliary Atresia

Start: 2013-10-31End: 2016-07-31Updated: 2019-10-01

Safety and Tolerability of M254 in Healthy Volunteers and Immune Thrombocytopenic Purpura (ITP) Patients

TerminatedNCT03866577

Momenta Pharmaceuticals, Inc.Immune Thrombocytopenic Purpura (ITP)

Start: 2018-12-21End: 2021-06-09Updated: 2025-05-28

Phase 1 Study of ART5803 Safety and PK After IVIG in Healthy Participants

Active, not recruitingNCT06753955

Arialys TherapeuticsAutoimmune Encephalitis, Autoimmune Encephalitis Caused by N-Methyl D-Aspartate Receptor Antibody, Autoimmune Encephalitis Caused by N-Methyl D-Aspartate Receptor Antibody (Disorder)

Start: 2025-03-18End: 2025-12-24Target: 6Updated: 2025-09-25

Phase 2

Intravenous Immunoglobulin (IVIg) for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

CompletedNCT00001287

National Institute of Neurological Disorders and Stroke (NINDS)Demyelinating Diseases, Paraproteinemias

Start: 1990-12-31End: 2001-01-31Target: 60Updated: 2008-03-04

Stem Cell Transplant for Immunologic or Histiocytic Disorders

CompletedNCT00176865

Masonic Cancer Center, University of MinnesotaChediak-Higashi Syndrome, Griscelli Syndrome, Hemophagocytic Lymphohistiocytosis +3

Start: 2002-08-31End: 2014-08-31Updated: 2017-12-28

Treatment of Multiple System Atrophy Using Intravenous Immunoglobulins

CompletedNCT00750867

University of Massachusetts, WorcesterMultiple System Atrophy

Start: 2008-06-30End: 2012-12-31Updated: 2017-02-23

Ig PRx in AECOPD: Pilot Study

CompletedNCT02690038

Ottawa Hospital Research InstituteChronic Obstructive Pulmonary Disease

Start: 2016-09-30End: 2019-11-20Updated: 2019-11-27

BIVV020 (SAR445088) in Prevention and Treatment of Antibody-mediated Rejection (AMR)

Active, not recruitingNCT05156710

SanofiTransplant Rejection

Start: 2022-06-09End: 2026-10-26Updated: 2026-02-24

Therapies for Down Syndrome Regression Disorder

Active, not recruitingNCT05662228

University of Colorado, DenverDown Syndrome, Regression

Start: 2023-06-29End: 2026-12-01Target: 66Updated: 2026-02-27

Evaluating Efgartigimod in Patients With Guillain-Barré Syndrome

WithdrawnNCT05701189

Chafic KaramGuillain-Barre Syndrome

Start: 2024-09-10End: 2026-02-20Updated: 2026-03-12

Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Platform Trial (RATIONAL-PT)

RecruitingNCT07202052

Monash UniversityLeukemia, Myeloma, Non-Hodgkin's Lymphoma

Start: 2025-05-06End: 2027-03-31Target: 900Updated: 2025-10-07

Phase 3

V-IMMUNE: A Novel Immunoglobulin Therapy for Immunodeficiency

RecruitingNCT06954441

On Pharma Importadora, Exportadora e Distribuidora de Medicamentos LTDA.Agammaglobulinemia, Immunodeficiencies, Primary Immunodeficiencies (PID)

Start: 2025-08-15End: 2027-02-27Target: 50Updated: 2026-01-20

Intravenous Immunoglobulin for the Treatment of Acute Exacerbations of Idiopathic Pulmonary Fibrosis

RecruitingNCT07299695

Argyrios TzouvelekisAcute Exacerbation of Idiopathic Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis

Start: 2026-01-25End: 2028-12-01Target: 196Updated: 2026-03-16

Phase 4

A Study of ELAPRASE in Treatment-naïve Participants With Hunter Syndrome (Mucopolysaccharidosis [MPS] II)

WithdrawnNCT05494593

TakedaHunter Syndrome, Mucopolysaccharidosis (MPS)

Start: 2023-02-28End: 2025-08-29Updated: 2025-12-09

Related Papers

JAK inhibition decreases the autoimmune burden in Down syndrome

eLife2024-08-0816 citations

A Randomized Double-Blind Placebo-Control Feasibility Trial of Immunoglobulin Treatment for Prevention of Recurrent Acute Exacerbations of COPD

International Journal of COPD2021-12-011 citations

Hyper-Sialylated IgG M254, an Innovative Therapeutic Candidate, Evaluated in Healthy Volunteers and in Patients with Immune Thrombocytopenia Purpura: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics

Blood2019-11-1311 citations

A Phase I/IIa Trial of Intravenous Immunoglobulin Following Portoenterostomy in Biliary Atresia

Journal of Pediatric Gastroenterology and Nutrition2019-01-2436 citations

Study protocol: a randomized, double-blind, parallel, two-arm, placebo control trial investigating the feasibility and safety of immunoglobulin treatment in COPD patients for prevention of frequent recurrent exacerbations

Pilot and Feasibility Studies2018-08-115 citations